cbdMD, Inc. YCBD

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
39/100
Developing

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

About cbdMD, Inc.

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD … Full YCBD analysis →

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.80), with margins expanding over time.

Key risks

  • ROIC Below WACC or Peers ROIC at 28.9th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.18), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
28
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where YCBD ranks in Drug Manufacturers - Specialty & Generic

cbdMD, Inc. ranks #52 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 57%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
48 Lifecore Biomedical, Inc. LFCR 40/100 Developing
49 Evolus, Inc. Common Stock EOLS 39/100 Developing
50 Regencell Bioscience Holdings L RGC 39/100 Developing
51 Sonoma Pharmaceuticals, Inc. SNOA 39/100 Developing
52 cbdMD, Inc. YCBD 39/100 Developing
53 BGM Group Ltd. BGM 37/100 Developing
54 Biofrontera Inc. BFRI 37/100 Developing
55 Biofrontera Inc. Warrants BFRIW 37/100 Developing
56 IM Cannabis Corp. IMCC 37/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How YCBD scores on the Corporate Default defenses

Pricing Power

Score 28 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 41 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 50 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 25 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 32 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 64 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding YCBD's moat

What is cbdMD, Inc.'s moat score?

cbdMD, Inc. (YCBD) scores 39 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #52 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 57%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (64/100) and its weakest is Capital Efficiency (25/100).

How does cbdMD, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

cbdMD, Inc. ranks #52 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Sonoma Pharmaceuticals, Inc. (SNOA) at 39 just above it and BGM Group Ltd. (BGM) at 37 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is cbdMD, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for cbdMD, Inc.?

The Corporate Default template measures 6 defenses, and YCBD scores: Pricing Power (28), Cost Advantage (41), Customer Stickiness (50), Capital Efficiency (25), Resilience (32), Scale & Market Position (64). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000